VUSE ALTO UNAFFECTED BY RECENT FDA DECISION ON VUSE SOLO MENTHOL

The U.S. Food and Drug Administration (FDA) denied premarket tobacco product applications (PMTA) for our Vuse Solo Replacement Cartridge Menthol 4.8%.  

  • This denial does not impact the legal status of Vuse Alto’s PMTA, which is awaiting further review by FDA. 
  •  This denial also does not impact the prior marketing authorizations for the Vuse Solo Power Unit and Vuse Solo Replacement Cartridge Original 4.8%.

We are disappointed in this decision. We are pursuing appropriate legal avenues in order to allow Vuse to continue offering its innovative products to adult nicotine consumers age 21+ without interruption. Although we disagree with the FDA’s decision, we remain committed to working alongside the agency to create A Better Tomorrow™.

Thank you for your patience as we navigate this process.  We will continue to provide important updates as additional information becomes available.

The Vuse Team